Boston Seminar Series | IP and the Business of Biopharma: Lessons Learned (Sometimes the Hard Way)


Fish principals Teresa Lavoie and Anita Meiklejohn moderated a panel discussion with business leaders and in-house IP practitioners from the Boston area in this year's second installment of the Boston Seminar Series at Glass House, 450 Kendall St, Cambridge, MA.

The panel provided an insider’s perspective on the strategic role that intellectual property plays in the business model of biopharma companies, covering the following topics:

  • Defining success
  • Licensed portfolios v. company-owned IP
  • Global filing strategies
  • Exit strategy considerations
  • Technology platforms and challenges for early stage companies


Damon Banks
Compass Therapeutics
Senior Patent Attorney

Christine Bellon
Relay Therapeutics, Inc.
Senior Vice President, Legal Affairs

Janice Klunder, Ph.D., J.D.
Ipsen Bioscience, Inc.
VP, IP – Endocrinology and R&D Peptides

Ann D. Kwong, Ph.D.
TREK Therapeutics
Founder and CEO

Thomas McMurry
WntRx Pharmaceuticals